MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29
WESTLAKE VILLAGE, Calif., June 25, 2021 /PRNewswire/ --MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative medicines for patients with endocrine and orphan lung diseases, will present two posters at the American Diabetes Association's virtual 81st Scientific Sessions, June 25-29.
- WESTLAKE VILLAGE, Calif., June 25, 2021 /PRNewswire/ --MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative medicines for patients with endocrine and orphan lung diseases, will present two posters at the American Diabetes Association's virtual 81st Scientific Sessions, June 25-29.
- MannKind is also hosting a booth in the virtual Exhibit Hall at the Scientific Sessions.
- An insulin regimen that closely mimics physiologic insulin for pediatric patients with type 1 diabetes (T1D) remains a critical goal.
- Afrezza an ultra rapid-acting dry-powder prandial insulin is currently indicated to improve glycemic control in adults with T1D or type 2 (T2D) diabetes.